

REMARKS

This Response is being submitted in response to the Restriction Requirement mailed March 23, 2004.

The status of the claims is as follows.

Claims 3-10, 16-28, 31, and 34-43 have been canceled.

Claims 1-2, 11-15, 29-30, 32-33, and 44-51 are pending in this application.

Applicants are required to elect one of the following inventions for further prosecution on the merits:

- Group I - Claims 1-2 and 11-15, drawn to compounds and compositions;
- Group II - Claims 29-30, drawn to method for inhibition of interaction of RAGE with its physiological ligands;
- Group III - Claims 32-33 (in part), drawn to a method for treatment;
- Group IV - Claims 32-33 (in part), drawn to a method for treatment;
- Group V - Claims 32-33 (in part), drawn to a method for treatment;
- Group VI - Claims 32-33 (in part), drawn to a method for treatment;
- Group VII - Claims 32-33 (in part), drawn to a method for treatment;
- Group VIII - Claims 32-33 (in part), drawn to a method for treatment;
- Group IX - Claims 32-33 (in part), drawn to a method for treatment;
- Group X - Claims 32-33 (in part), drawn to a method for treatment;
- Group XI - Claim 44, drawn to a method for preparing compounds of formula II;
- Group XII - Claim 45, drawn to a method for preparing compounds of formula III;
- Group XIII - Claim 46, drawn to a method for preparing compounds of formula IV;
- Group XIV - Claim 47, drawn to a method for preparing compounds of formula V;
- Group XV - Claim 48, drawn to a method for preparing compounds of formula V;
- Group XVI - Claim 49, drawn to a method for preparing compounds of formula VI;
- Group XVII - Claim 50 (in part), drawn to a method for preparing compounds of formula VII;

Group XVIII - Claim 50 (in part), drawn to a method for preparing compounds of formula VII;

Group XIX - Claim 50 (in part), drawn to a method for preparing compounds of formula VII;

Group XX - Claim 51, drawn to a method for preparing compounds of formula VIII.

Further, Applicants are required to elect a single disclosed species from within the elected Group for search purposes.

Applicants elect, with traverse, the claims of Group I (claims 1-2 and 11-15). Applicants elect the species of compound ((R)-3-(4-Benzoyloxyphenyl)-2-tert-butoxycarbonylaminopropionic Acid 4-(3-Diethylamino-1-propoxy)-2-(3-diethylamino-1-propoxy)aniline Amide) shown as Example 21 on page 39 of the application for search purposes. Applicant traverses the election of Group I, and the species of Example 21, on the grounds that searching all of the claims would not prove unduly burdensome.

Amendments

Applicants have amended claims 1 and 2. In claim 1, Applicants have further defined the structure of the at least one lipophilic group substituted on the Aryl₂ group. Support for this amendment can be found in the specification in Examples 3-4, 8-9, 13-24, and 26 where each compound disclosed comprises an Aryl₂ group substituted with at least one lipophilic group selected from the group consisting of: -Y-C₁-C₆ alkyl-NR₇R₈.

In claim 2, Applicants have revised the wording of the claim to more clearly articulate that at least one of Aryl₁ and Aryl₂ is substituted with a lipophilic group selected from the group consisting of C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylaryl, and C₁-C₆ alkoxyaryl. Support for this amendment can be found in the specification in Examples 3-4, 8-9, 13-24, and 26 where each compound disclosed comprises at least one Aryl₁ or Aryl₂ substituted

with a lipophilic group selected from the group consisting of C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylaryl, and C₁-C₆ alkoxyaryl.

Fees

Applicants are submitting this complete response to the Office Action mailed March 23, 2004, before the 2 month due date of May 23. As a result, Applicants have included with this response a request for a 1 month extension and a check for a 1 month extension fee of \$55. Applicants believe no other fee is due.


CONCLUSION

Favorable consideration and allowance of the application are respectfully requested.

Should the Examiner believe that anything further is necessary to place the application in a condition for allowance, the Examiner is invited to contact the undersigned attorney at the telephone number listed below.

Date: May 17, 2004

Respectfully submitted,

By: 
Samuel B. Rollins
Reg. No. 52,180

KILPATRICK STOCKTON LLP
1001 West Fourth Street
Winston-Salem, North Carolina 27101
(336) 607-7432
(336) 734-2651